LESSENGERS Demonstrates 800G QSFP-DD and 400G QSFP112 Optical Transceivers
12.9.2022 13:00:00 EEST | Business Wire | Press release
LESSENGERS Inc. (“LESSENGERS”), an innovative optical interconnect solution provider, announced today, a live demonstration of polymer-wired 800G QSFP-DD and 400G QSFP112 optical transceivers without the use of any lens optics, providing excellent performance and cost-effectiveness, during the ECOC 2022 (Stand 511 and MR31), the largest optical communications exhibition in Europe, on September 19 – 21, at Messe Basel, Switzerland.
Powered by LESSENGERS’s patent direct optical wiring (DOW) technology, the LESSENGERS 800G QSFP-DD and 400G QSFP112 optical transceivers achieve excellent optical signal integrity and best cost-effectiveness. This unique technology enables complete passive alignment with high-precision and -density optical coupling without the use of lens optics, providing the most suitable solutions for high-speed data center applications such as 800G/1.6T optical modules, on-board, near packaged or co-packaged optics.
“LESSENGERS will demonstrate a set of 112G and 56G signaling-based products during the show, ECOC 2022 on September 19 – 21 to support our customers in urgent needs and will be adding products in the upcoming quarters to complete its product portfolio,” said Taeyong Kim, CMO at LESSENGERS.
“LESSENGERS’s current business is focused on multimode-based optical interconnect solutions along with customized optical packaging services, however, we will continue to push forward on single-mode-based applications such as silicon photonics,” added Chongcook Kim, CEO at LESSENGERS. “This successful demonstration of DOW technology-based optical transceiver solutions will bring a new era of data center optical interconnects and the development of these technologies will support future requirements for high performance computing (HPC) and artificial intelligence (AI) solutions.
LESSENGERS’s demonstration will be with:
- 800G QSFP-DD SR8 optical transceiver
- 400G QSFP112 SR4 optical transceiver
- 200G QSFP56 SR4 optical transceiver
- 200G ultra-small sized optical module
About LESSENGERS
LESSENGERS Inc. is an innovative optical interconnect solution provider. Its patent direct optical wiring (DOW) technology enables high-precision and high-density submicrometer scale optical coupling between high-speed photonic devices and various optical waveguides with the best cost-effectiveness. LESSENGERS’s 800G/400G/200G optical transceiver/active optical cable solutions are powered by the high-performance manufacturing-oriented DOW technologies.
Please visit www.lessengers.com for more information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005022/en/
Contact information
LESSENGERS Inc.
Taeyong Kim, Ph.D
Chief Marketing Officer
+82-10-6549-7654
taeyong.kim@lessengers.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release
Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release
The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release
Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom